Search results for "Growth factor"

showing 10 items of 1300 documents

Tbx1 regulates Vegfr3 and is required for lymphatic vessel development

2010

Defects in lymphangiogenesis are added to the broad clinical manifestations of DiGeorge syndrome, caused by deletion of the T box transcription factor Tbx1.

Vascular Endothelial Growth Factor ATBX1Cellular differentiationBiologyMice03 medical and health sciences0302 clinical medicinestomatognathic systemReportLymphatic vesselmedicineAnimalsHumansLymphangiogenesisEnhancerCells CulturedResearch ArticlesLymphatic Vessels030304 developmental biology0303 health sciencesABNORMAL CAROTID ARTERIES; TRANSGENIC MICE; VELOCARDIOFACIAL SYNDROME; CARDIOVASCULAR DEFECTS; LYMPHANGIOGENESIS; LYMPHEDEMA; MOUSE; RECEPTOR-3; MUTATION; SYSTEMEndothelial CellsGene Expression Regulation DevelopmentalCell DifferentiationCell BiologyEmbryo Mammalian3. Good healthLymphangiogenesisCell biologyVascular endothelial growth factor ALymphatic systemmedicine.anatomical_structureVascular endothelial growth factor Cembryonic structuresImmunologyT-Box Domain Proteins030217 neurology & neurosurgeryJournal of Cell Biology
researchProduct

Microphthalmia, persistent hyperplastic hyaloid vasculature and lens anomalies following overexpression of VEGF-A188 from the αA-crystallin promoter

2007

Purpose During growth of the embryonic eye, dose- and site-specific expression of heparin-binding growth factors is critical for the formation of an appropriate vascular supply. Overexpression of vascular endothelial growth factor-A188 (VEGF-A188), a strongly heparin-binding, endothelial-specific mitogen, leads to severe disturbance of vascular and overall ocular morphology. This study aimed to evaluate the effects of VEGF-A188 overexpression on growth of ocular tissue components. Methods Stereological and immunohistochemical methods were employed to identify the vascular profiles, ocular tissue proportions, and cell types in VEGF-A188 transgenic mice and compare them with wild-type mice. R…

Vascular Endothelial Growth Factor Agenetic structuresMyocytes Smooth MuscleCell CountMice TransgenicEyealpha-Crystallin A ChainCongenital AbnormalitiesCorneaMiceLens CrystallineAnimalsMicrophthalmosVascular DiseasesPromoter Regions GeneticHyperplasiaEndothelial CellsHypertrophyEmbryo MammalianAntigens DifferentiationImmunohistochemistryeye diseasesActinsDisease Models AnimalAnimals NewbornBlood Vesselssense organsPericytesHeparan Sulfate ProteoglycansResearch ArticleMolecular Vision
researchProduct

Comparative study assessing effects of sonic hedgehog and VEGF in a human co-culture model for bone vascularisation strategies.

2011

The morphogen sonic hedgehog (Shh) seems to mediate adult repair processes in bone regeneration and vascularisation. In this study we investigated the effects of Shh on co-cultures consisting of human primary osteoblasts and outgrowth endothelial cells in terms of angiogenic activation and vessel maturation in comparison to the treatment with the commonly used proangiogenic factor, VEGF. Both, stimulation with VEGF or Shh, leads to an increase in the formation of microvessel-like structures compared to untreated controls. In contrast to VEGF, proangiogenic effects by Shh could already be observed after 24 h of treatment. Nevertheless, after 14 days the angiogenic activity of OEC was compara…

Vascular Endothelial Growth Factor Alcsh:Diseases of the musculoskeletal systemBone Regenerationmedicine.medical_treatmentFluorescent Antibody TechniqueAngiogenesis InhibitorsPolymerase Chain ReactionneovascularisationBasement MembraneDesminchemistry.chemical_compoundTransforming Growth Factor betaReceptors Platelet-Derived Growth FactorSonic hedgehogbiologyCell biologyUp-Regulationembryonic structuresElectrophoresis Polyacrylamide GelMorphogenmedicine.medical_specialtyanimal structuressignalling moleculesCyclopamineBlotting Westernlcsh:SurgeryNeovascularization PhysiologicEnzyme-Linked Immunosorbent AssayBone and BonesDownregulation and upregulationInternal medicinemedicineAngiopoietin-1HumansHedgehog ProteinsBone regenerationOsteoblastsGrowth factorEndothelial Cellslcsh:RD1-811bone repairco-cultureActinsCoculture TechniquesEndocrinologychemistryMyocardinbiology.proteinDesminlcsh:RC925-935AngiopoietinsEuropean cellsmaterials
researchProduct

Predicting efficacy and toxicity in the era of targeted therapy: focus on anti-EGFR and anti-VEGF molecules

2011

The treatment of solid malignancies includes various target drugs, such as monoclonal antibodies and tyrosine kinase inhibitors, which exert their effect alone or in combination with chemotherapy. The main part of these molecules have a target on proteins of EGFR and VEGF pathways. The particular toxicity profile and the financial impact, deriving from the application of these agents in cancer treatment, prompted a lot of researches to define predictive factors of their efficacy. Various biomarker were identified among the components of the targeted pathways. However just few studies allowed to identify specific factors to predict the toxicity of these drugs. In this review EGFR and VEGF-re…

Vascular Endothelial Growth Factor Amedicine.drug_classSettore MED/06 - Oncologia Medicamedicine.medical_treatmentClinical BiochemistryAngiogenesis InhibitorsAntineoplastic AgentsPharmacologyMonoclonal antibodyTargeted therapyAntineoplastic AgentNeoplasmsProtein-Tyrosine KinasemedicineHumansAngiogenesis Inhibitors; Antibodies Monoclonal; Antineoplastic Agents; Humans; Neoplasms; Protein-Tyrosine Kinases; Receptor Epidermal Growth Factor; Treatment Outcome; Vascular Endothelial Growth Factor ATarget therapyPharmacologyAnti vegfChemotherapybusiness.industryAntibodies MonoclonalProtein-Tyrosine KinasesErbB ReceptorsTreatment OutcomeToxicityCancer researchBiomarker (medicine)NeoplasmReceptor Epidermal Growth FactorbusinessTyrosine kinaseAngiogenesis InhibitorHuman
researchProduct

Real-life patient journey in neovascular age-related macular degeneration: a narrative medicine analysis in the Italian setting

2021

Objectives To investigate the real-life experience of patients affected by neovascular age-related macular degeneration (nAMD), in the healthcare pathway for the management of the disease, using a "patient journey" and narrative method approach. Methods The patient journey of subjects affected by nAMD was designed using a process-mapping methodology involving a team from 11 Italian centres. Subsequently, narratives were collected from nAMD patients and family members. The interviews were analyzed using the narrative medicine methodology. Results Eleven specialized retina centres across Italy were involved and 205 narratives collected. In 29% of cases, patients underestimated their symptoms …

Vascular Endothelial Growth Factor Amedicine.medical_specialtyActivities of daily livingage related macular degenerationMEDLINEAngiogenesis InhibitorsDiseaseArticle03 medical and health sciencesMacular Degeneration0302 clinical medicineMultidisciplinary approachRanibizumabHealth carereal lifeMedicinepatient journeyHumansNarrativeeducationNarrative medicineeducation.field_of_studyNarrative medicine wet AMDbusiness.industrySettore MED/30 - Malattie Apparato VisivoNarrative MedicineMacular degenerationmedicine.diseaseOphthalmologyFamily medicineIntravitreal Injections030221 ophthalmology & optometryQuality of LifeWet Macular Degenerationbusiness030217 neurology & neurosurgery
researchProduct

Capillary enlargement, not sprouting angiogenesis, determines beneficial therapeutic effects and side effects of angiogenic gene therapy.

2010

Aims Currently, it is still unclear which mechanisms drive metabolic benefits after angiogenic gene therapy. The side-effect profile of efficient angiogenic gene therapy is also currently incompletely understood. In this study, the effects of increasing doses of adenoviral (Ad) vascular endothelial growth factor-A (VEGF-A) were evaluated on vascular growth, metabolic benefits, and systemic side effects. Methods and results Adenoviral vascular endothelial growth factor-A or AdLacZ control was injected intramuscularly (109–1011 vp/mL) or intra-arterially (5 × 1011 vp/mL) into rabbit ( n = 102) hindlimb muscles and examined 6 or 14 days later. Blood flow, tissue oedema, metabolic benefits, and…

Vascular Endothelial Growth Factor Amedicine.medical_specialtyAngiogenesisGenetic VectorsNeovascularization PhysiologicEnzyme-Linked Immunosorbent Assayta3111Injections IntramuscularAdenoviridaeNeovascularizationchemistry.chemical_compoundInternal medicinemedicineAnimalsMuscle SkeletalUltrasonography InterventionalSprouting angiogenesisDose-Response Relationship Drugbusiness.industryGene Transfer TechniquesMetabolic acidosisGenetic Therapymedicine.diseaseCapillariesHindlimbVascular endothelial growth factorVascular endothelial growth factor AEndocrinologychemistryLac OperonCirculatory systemRabbitsmedicine.symptomCardiology and Cardiovascular MedicinebusinessPerfusionEuropean heart journal
researchProduct

Dopamine agonist administration causes a reduction in endometrial implants through modulation of angiogenesis in experimentally induced endometriosis

2009

Survival of newly implanted retrograde-shed endometrial tissue during menstruation in an ectopic location requires an adequate blood supply. This suggests that angiogenesis is a prerequisite for the development of endometriosis and that its inhibition may be a target for preventing development. Previous studies have shown that vascular endothelial growth factor (VEGF), a heparin-binding glycoprotein, has an essential role in angiogenesis. The main regulatory factor for angiogenesis appears to be binding of VEGF to its type-2 receptor (VEGFR-2). Cabergoline (Cb2) and other dopamine agonists promote endocytosis of the VEGF receptor-2 (VEGFR-2) in endothelial cells, thereby preventing VEGF-VEG…

Vascular Endothelial Growth Factor Amedicine.medical_specialtyCabergolineProliferation indexAngiogenesisEndometriosisEndometriosisBiologyEndometriumDopamine agonistMicechemistry.chemical_compoundPeritoneumCabergolineInternal medicinemedicineAnimalsHumansErgolinesPhosphorylationReceptorCell ProliferationNeovascularization Pathologicbusiness.industryRehabilitationObstetrics and GynecologyKinase insert domain receptorGeneral Medicinemedicine.diseaseVascular Endothelial Growth Factor Receptor-2Vascular endothelial growth factorDisease Models AnimalVascular endothelial growth factor AEndocrinologymedicine.anatomical_structureGene Expression RegulationReproductive MedicinechemistryDopamine AgonistsFemalelipids (amino acids peptides and proteins)businessmedicine.drugHuman Reproduction
researchProduct

Tyrosine Phosphorylation Modulates the Vascular Responses of Mesenteric Arteries from Human Colorectal Tumors

2013

The aim of this study was to analyze whether tyrosine phosphorylation in tumoral arteries may modulate their vascular response. To do this, mesenteric arteries supplying blood flow to colorectal tumors or to normal intestine were obtained during surgery and prepared for isometric tension recording in an organ bath. Increasing tyrosine phosphorylation with the phosphatase inhibitor, sodium orthovanadate produced arterial contraction which was lower in tumoral than in control arteries, whereas it reduced the contraction to noradrenaline in tumoral but not in control arteries and reduced the relaxation to bradykinin in control but not in tumoral arteries. Protein expression of VEGF-A and of th…

Vascular Endothelial Growth Factor Amedicine.medical_specialtyContraction (grammar)Article SubjectMedicinaBradykininlcsh:MedicineBiologyGeneral Biochemistry Genetics and Molecular BiologyTyrosine phosphorylationchemistry.chemical_compoundOrgan Culture TechniquesInternal medicinemedicineHumansPhosphorylationTyrosineSodium orthovanadateMesenteric arteriesVascular Endothelial Growth Factor Receptor-1Neovascularization PathologicGeneral Immunology and Microbiologylcsh:RTyrosine phosphorylationGeneral MedicineMesenteric ArteriesGene Expression Regulation NeoplasticVascular endothelial growth factor AEndocrinologymedicine.anatomical_structurechemistryTyrosinePhosphorylationVanadatesColorectal NeoplasmsResearch ArticleBioMed Research International
researchProduct

Sonic hedgehog promotes angiogenesis and osteogenesis in a coculture system consisting of primary osteoblasts and outgrowth endothelial cells.

2009

A number of previous studies documented the angiogenic potential of outgrowth endothelial cells in vitro and in vivo and provided evidence that therapeutic success could depend on coculture or coimplantation strategies. Thus, deeper insight into the molecular mechanisms underlying this pro-angiogenic effect of cocultures might provide new translational options for tissue engineering and regenerative medicine. One promising signaling pathway in bone repair involved in neoangiogenesis and bone formation is the sonic hedgehog (Shh) pathway. In this article, we focus on the effect of Shh on the formation of microvessel-like structures and osteoblastic differentiation in cocultures of primary os…

Vascular Endothelial Growth Factor Amedicine.medical_specialtyCyclopamineAngiogenesisCellular differentiationBiomedical EngineeringNeovascularization PhysiologicBioengineeringBiochemistryBiomaterialsAngiopoietin-2chemistry.chemical_compoundOsteogenesisInternal medicinemedicineAngiopoietin-1HumansHedgehog ProteinsRNA MessengerSonic hedgehogBone regenerationDNA PrimersOsteoblastsbiologyBase SequenceTissue EngineeringVeratrum AlkaloidsEndothelial CellsCell DifferentiationOriginal ArticlesHedgehog signaling pathwayCoculture TechniquesRecombinant ProteinsCell biologyCapillariesUp-RegulationVascular endothelial growth factorVascular endothelial growth factor AEndocrinologychemistrybiology.proteinSignal TransductionTissue engineering. Part A
researchProduct

Risk of Death Associated With Intravitreal Anti-Vascular Endothelial Growth Factor Therapy: A Systematic Review and Meta-analysis.

2020

Importance Although intravitreal anti–vascular endothelial growth factor (VEGF) treatment represents the first-line therapy for many retinal diseases, the issue of their systemic safety is debatable. Objectives To assess whether intravitreal anti-VEGF therapy might be associated with increased risk of mortality and which variables are associated with the increase. Data Sources PubMed, MEDLINE, and Embase databases, the Cochrane Library, and ClinicalTrials.gov were systematically searched from inception to May 6, 2019. Study Selection Randomized clinical trials comparing intravitreal anti-VEGF treatment with control groups and with follow-up of at least 6 months were selected. Data Extractio…

Vascular Endothelial Growth Factor Amedicine.medical_specialtyDatabases FactualMEDLINEAngiogenesis InhibitorsCochrane LibraryMacular Edemalaw.inventionRandomized controlled triallawFrequentist inferenceInternal medicineCause of DeathRetinal Vein OcclusionMedicineHumansanti-VEGF therapyrisk of mortality anti-vascular endothelial growth factor mortalityCause of deathOriginal InvestigationRandomized Controlled Trials as TopicDiabetic Retinopathybusiness.industryMortality rateOdds ratioChoroidal NeovascularizationOphthalmologyMeta-analysisIntravitreal InjectionsWet Macular DegenerationbusinessJAMA ophthalmology
researchProduct